» Articles » PMID: 39868377

Harnessing Machine Learning to Predict Prostate Cancer Survival: a Review

Overview
Journal Front Oncol
Date 2025 Jan 27
PMID 39868377
Authors
Affiliations
Soon will be listed here.
Abstract

The prediction of survival outcomes is a key factor in making decisions for prostate cancer (PCa) treatment. Advances in computer-based technologies have increased the role of machine learning (ML) methods in predicting cancer prognosis. Due to the various effective treatments available for each non-linear landscape of PCa, the integration of ML can help offer tailored treatment strategies and precision medicine approaches, thus improving survival in patients with PCa. There has been an upsurge of studies utilizing ML to predict the survival of these patients using complex datasets, including patient and tumor features, radiographic data, and population-based databases. This review aims to explore the evolving role of ML in predicting survival outcomes associated with PCa. Specifically, we will focus on the applications of ML in forecasting biochemical recurrence-free, progression to castration-resistance-free, metastasis-free, and overall survivals. Additionally, we will suggest areas in need of further research in the future to enhance the utility of ML for a more clinically-utilizable PCa prognosis prediction and treatment optimization.

References
1.
Wong N, Lam C, Patterson L, Shayegan B . Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy. BJU Int. 2018; 123(1):51-57. DOI: 10.1111/bju.14477. View

2.
Thurairaja R, Studer U, Burkhard F . Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist. 2009; 14(1):40-51. DOI: 10.1634/theoncologist.2008-0123. View

3.
Wang X, Zhang X, Li H, Zhang M, Liu Y, Li X . Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer. J Cancer Res Clin Oncol. 2023; 149(11):8759-8768. PMC: 10374763. DOI: 10.1007/s00432-023-04816-w. View

4.
Lopez-Abad A, Backhaus M, Server Gomez G, Cao Avellaneda E, Moreno Alarcon C, Lopez Cubillana P . Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. Prostate Int. 2024; 12(1):20-26. PMC: 10960092. DOI: 10.1016/j.prnil.2023.10.003. View

5.
Hou Y, Bao J, Song Y, Bao M, Jiang K, Zhang J . Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer. EBioMedicine. 2021; 68:103395. PMC: 8167242. DOI: 10.1016/j.ebiom.2021.103395. View